The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of care in the treatment of newly diagnosed GBM patients. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields) to the region of the malignant tumor, by means of surface, insulated electrodes.

Currently trained sites

Dr. Eric T. Wong, Beth Israel Deaconess Medical Center in Boston, Massachusetts

Dr. Lisa DeAngelis, Memorial Sloan Kettering Cancer Center, New York, New York

Dr. Jay-Jiguang Zhu, Mischer Neuroscience Institute in the Memorial Hermann Hospital, Houston, Texas

Dr. Joseph Landolfi, New Jersey Neuroscience Institute at JFK, Edison, New Jersey

Dr. Herbert Engelhard, University of Illinois Hospital in Chicago, Illinois

Dr. Andrew Lassman, NewYork-Presbyterian/Columbia University Medical Center, New York, New York

Dr. Santosh Kesari, University of California San Diego Moores Cancer Center, San Diego, California

Access to cutting-edge treatments like NovoCure’s NovoTTF means more options and more hope for patients battling brain cancer. This is what patients and doctors need to maintain this disease.